|
Day 1. Friday, 13 October 2023
1.50pm to 8pm
|
|
Time
|
Title
|
Speakers
|
|
Moderators: Dr. Salha Bujassoum & Dr.
Cicy Mary Jacob
|
|
1pm to 1.50pm
|
Registration
|
|
|
1.50pm to 2.05pm
|
Welcome and Opening Remarks
|
Dr. Mohamed Salem Jaber Al-Hassan
CEO & Medical Director, NCCCR Chairman, Corporate Cancer Services, HMC
Dr. Mohammed Ussama Al Homsi
Deputy Medical Director for Education, Research and Quality, Senior
Consultant Medical Oncologist, NCCCR
|
|
2.05pm to 2.25pm
|
Breast Cancer - Local Regional Adjuvant Track (Abstract 501):
Efficacy and Safety Results by Age in Monarche: adjuvant abemaciclib combined
with endocrine therapy (ET) in patients with HR+, HER2-, node-positive,
high-risk early breast cancer (EBC)
|
Dr. Salha Bujassoum
Chair of Medical Oncology and Palliative Care, Senior Consultant
Medical Oncologist, NCCCR
|
|
2.25pm to 2.45pm
|
Breast Cancer - Local Regional Adjuvant Track (Abstract LBA500):
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment
in patients with HR+/HER2− early breast cancer
|
Dr. Francois Calaud
Senior Consultant Medical Oncologist, NCCCR
|
|
2.45p to 3.05pm
|
Breast Cancer - Local Regional Adjuvant Track (Abstract 503):
Effects of ovarian ablation or suppression on breast cancer recurrence and
survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25
randomized trials
|
Dr. Nabeeha Karadawi
Consultant Medical Oncologist, NCCCR
|
|
3.05pm to 3.20pm
|
PANEL DISCUSSION
|
|
3.20pm to 3.40pm
|
Prayer & Coffee Break
|
|
Moderators: Dr. Nabeeha Karadawi & Dr.
Francois Calaud
|
|
3.40pm to 4pm
|
Breast Cancer - Metastatic (Abstract 1003): Final overall
survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab
govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative
(HR+/HER2–) metastatic breast cancer (mBC)
|
Dr. Ahlam Yousif
Consultant Medical Oncologist, NCCCR
|
|
4pm to 4.20pm
|
Breast Cancer - Metastatic (Abstract 1007): Randomized trial
of fixed dose capecitabine compared to standard dose capecitabine in metastatic
breast cancer: The X-7/7 trial
|
Dr. Cicy Mary Jacob
Consultant Medical Oncologist, NCCCR
|
|
4.20pm to 4.40pm
|
Breast Cancer - Metastatic (Abstract LBA1000): Primary
outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the
optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for
patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced
breast cancer (ABC)
|
Dr. Mohammed Gaber
Medical Oncologist, NCCCR
|
|
4.40pm to 5pm
|
Gynecologic (Abstract 5509): Final survival analysis of the
phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in
ovarian cancer after 10-year follow-up
|
Dr. Hind El Malik
Senior Consultant Medical Oncologist, NCCCR
|
|
5pm to 5.20pm
|
Gynecologic (Abstract 5503): Dostarlimab for primary
advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded
independent central review (BICR) of the RUBY trial
(ENGOT-EN6-NSGO/GOG-3031/RUBY)
|
Dr. Shaza Bek
Medical Oncologist, NCCCR
|
|
5.20pm to 5.35pm
|
PANEL DISCUSSION
|
|
5.35pm to 5.55pm
|
Prayer & Coffee Break
|
|
Moderators: Dr. Hind El Malik & Dr.
Asma El Hassan
|
5.55pm to 6.10pm
|
Symptom and Survivorship (Abstract 12000): A multicenter
randomized controlled trial (RCT) for the effectiveness of Comprehensive
Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL)
in older patients with solid tumors receiving systemic therapy: G-oncoCOACH
study
|
Ms. Wafa AlSaadi
Clinical Nurse Specialist
NCCCR
|
|
6.10pm to 6.25pm
|
Symptom and Survivorship (Abstract 12006): Reduced symptom
burden after implementation of an electronic symptom management program
|
Ms. Asma Younus
Clinical Nurse Specialist
NCCCR
|
|
6.25pm to 6.40pm
|
Symptom and Survivorship (Abstract 1507):
A cognitive-behavioral digital therapeutic for anxiety and depression in
patients with cancer: A decentralized randomized controlled trial
|
Ms. Gulfama AbidullahMuhammad
Clinical Nurse Specialist
NCCCR
|
|
6.40pm to 7pm
|
Developmental Therapeutics – Immunotherapy (Abstract 2509): Clinical
and immune phenotypes associated with immune checkpoint inhibitor-induced
autoimmune diabetes
|
Dr. SaidDermime
Director for Cancer Translational Research Facility, NCCCR
|
|
7pm to 7.20pm
|
Sarcoma (Abstract 11503): A multicenter phase II study of
cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS)
previously treated with a taxane (Alliance A091902)
|
Dr. Asma El Hassan
Senior Consultant Medical Oncologist, NCCCR
|
|
7.20pm to 7.40pm
|
Melanoma/Skin Cancers (Abstract LBA9503): Distant
metastasis-free survival results from the randomized, phase 2
mRNA-4157-P201/KEYNOTE-942 trial
|
Dr. Ashraf Awadelkarim
Associate Consultant Medical Oncologist, NCCCR
|
|
7.40pm to 8pm
|
PANEL DISCUSSION
|
|
8pm
|
Closing & Dinner
|
